Q3 26 was broadly in line with expectations, with FY27 China Dx remaining the core downside risk

Overview

This report is Goldman Sachs' Q3 26 earnings review and valuation update for Siemens Healthineers AG. It argues that while company Q3 26 total revenue was slightly below consensus, EBIT/EPS broadly matched expectations. In the medium term, the company is constructive on the Imaging and Precision Therapy businesses that make up the core synergy set, but remains cautious on EPS recovery in Diagnostics, particularly China Dx, in FY27 and therefore maintains a Neutral rating.

Core views

The key views are: first, Q3 26 group revenue growth was below consensus but profit was broadly in line with consensus; second, cost pressure, FX, and supply-chain inflation kept segment margins under year-over-year pressure; third, unified China IVD pricing, Hemostasis VBP, DRG 3.0 and import-substitution trends may constrain Diagnostics recovery; fourth, the absence of positive EPS upgrades and valuation pressure from Siemens AG stake reductions could still weigh on the stock; fifth, a potential Diagnostics spin-off is a long-term positive catalyst but is not enough to change the current Neutral view.

Analysis framework

The report combines Goldman Sachs forecasts, Visible Alpha consensus, segment revenue and margin assumptions, peer feedback from the Chinese diagnostics industry, and DCF and relative valuation methods to assess Q3 26 results, FY27 earnings risks, and the 12-month target price.

Methodology notes

• Valuation methodsDCF/Multiple blended valuation

  50% DCF and 50% P/E multiple blended valuation

  The 12-month target price of €42 is derived from a 50% DCF and 50% multiple blend; the DCF implies intrinsic value of €41.6 per share using 7.6% WACC and 2% terminal growth; the multiple method uses 16x P/E and implies €42.2 per share.

• Relative expectation comparisonGS forecast vs Visible Alpha Consensus

  Comparison of Goldman Sachs forecast with market consensus

  The report compares Goldman Sachs forecasts for revenue, organic growth, adjusted EBIT, margins and EPS against Visible Alpha consensus item by item, to judge whether earnings are above expectations or facing downside risks.

• Risk assessmentChina Diagnostics policy risk assessment

  China diagnostics business policy risk framework

  The report evaluates the impact of Hemostasis VBP, unified IVD pricing, DRG 3.0, reagent ASP declines, and import substitution on the recovery of Diagnostics revenue and margins.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Siemens Healthineers AG (SHLG.DE)

  coverage target

  Strengths

  The medium-term fundamentals of Imaging and Precision Therapy remain stable, group Q3 26 EBIT/EPS were broadly in line with consensus, and a potential Diagnostics spin-off could improve growth and margin structure.

  Weaknesses

  Diagnostics growth and margins are under pressure, FY27 EPS is below consensus, there are no positive earnings upgrades, and Siemens AG stake sales are creating technical and valuation pressure.

  Comparison

  Compared with Visible Alpha consensus, Goldman Sachs is slightly below on Q3 26 sales, roughly in line on EBIT/EPS, and 4% below on FY27 EPS, with Diagnostics EBIT significantly below consensus.

  Risks

  Chinese IVD policy, Hemostasis VBP, DRG 3.0, reagent ASP declines, import substitution, order slowdown, supply-chain constraints, and market-share loss.

• Diagnostics

  main source of risk and potential spin-off candidate

  Strengths

  If spun off, it could raise the group's organic growth and margins and accelerate deleveraging through cash proceeds.

  Weaknesses

  The China business is under policy and pricing pressure; Q3 sales are expected to decline and margins are significantly below last year.

  Comparison

  Goldman Sachs FY27 Diagnostics adjusted EBIT is €111m, about 40% below consensus of €196m.

  Risks

  Chinese unified pricing, Hemostasis VBP, DRG 3.0, import substitution, and reagent price declines.

• Imaging

  core business segment

  Strengths

  Q3 26 is expected to show 5% organic growth, sales of €3,056m, adjusted EBIT of €694m, and a margin of 22.7%.

  Weaknesses

  Growth slowed versus Q2 26, and margins are under year-over-year pressure from FX and supply-chain inflation.

  Comparison

  Sales are about 1% below consensus, while adjusted EBIT is about 1% above consensus.

  Risks

  High base effect, FX, cost inflation, and supply-chain pressures.

• Precision Therapy

  core business segment

  Strengths

  Q3 26 is expected to show 7% organic growth, supported by new product launches in Advanced Therapies, with adjusted EBIT expected at €238m.

  Weaknesses

  Margins declined year-over-year and remain affected by FX and supply-chain inflation.

  Comparison

  Sales are about 1% below consensus, while adjusted EBIT is about 1% above consensus.

  Risks

  New product ramp slower than expected, FX, and cost pressure.

Key data

• 12-month target price€42.00Target price unchanged.
• Current stock price€35.25Price disclosed on the cover page.
• Implied upside19.1%Based on €42 target price and €35.25 current price.
• Q3 26 organic revenue growth forecast4.1%Below Visible Alpha consensus of 4.8%.
• Q3 26 sales forecast€5,783mAbout 1% below consensus.
• Q3 26 adjusted EBIT forecast€899mBroadly in line with consensus.
• Q3 26 adjusted EBIT margin forecast15.6%Down about 130 bps year-over-year, mainly due to cost, FX, and supply-chain inflation.
• FY27 adjusted EPS versus consensus-4%Goldman Sachs forecast is below Visible Alpha consensus, mainly driven by Diagnostics and refinancing-related financial cost pressure.
• FY27 Diagnostics adjusted EBIT forecast€111mAbout 40% below consensus of €196m.
• Potential Diagnostics spin-off valuationaround €6bnEstimated valuation from media reports; the report says if it happens, it could lift growth and margins and accelerate deleveraging.
• Market capitalization€39.5bn / $45.1bnDisclosed on cover page.
• Enterprise value€51.6bn / $59.0bnDisclosed on cover page.
• 12-month forward P/E14.5xBased on updated estimates.
• EV/EBITDA11.1xBased on updated estimates.

Impact & implications

For investors, the report signals that profits are broadly holding but the upside revision momentum is limited. The target price shows nominal upside potential, but a Neutral rating indicates the analyst believes FY27 Diagnostics risks, the absence of positive EPS revisions, China policy disruptions, and parent-company sell-down pressure constrain risk-adjusted returns. If a Diagnostics spin-off proceeds or Chinese hospital capital spending rebounds, valuation narrative could improve; if policy-driven price cuts, faster import substitution, or slowing orders in China worsen, FY27 profitability and the target price face downside risk.

Risks

• Chinese hospital capex and order growth materially decelerate.
• Anti-corruption measures, unified pricing, Hemostasis VBP, or DRG 3.0 continue to have persistent negative effects.
• Diagnostics profit recovery is slower than expected, with declines in reagent ASP or faster import substitution.
• Supply-chain constraints, cost inflation, and FX swings suppress margins.
• Loss of market share or Varian synergies falling short of expectations.
• Ongoing technical valuation pressure from Siemens AG stake sell-downs.

What to watch

• The gaps between actual Q3 26 sales, organic growth, adjusted EBIT and EPS versus consensus.
• Diagnostics orders, reagent pricing, margins, and policy rollout pace in China.
• Whether the NHSA diagnostic service pricing project guidance is published in summer 2026 and implemented in 4Q26 or 1H27.
• Latest feedback from Chinese peers such as Mindray and SNIBE on IVD pricing, DRG 3.0, and import substitution.
• Whether a potential Diagnostics spin-off progresses in the next 24 months, its transaction valuation, and use of proceeds.
• Siemens AG reduction pace and its impact on stock price and valuation multiples.
• Whether FY26-FY28 EPS receives any upside revisions.